Category: ACN Newswire

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI(R)” for the Treatment of Early Alzheimer’s Disease in Japan

TOKYO and CAMBRIDGE, Mass., Nov. 28, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai

More